Select a medication above to begin.
Paxlovid
nirmatrelvir and ritonavir
Black Box Warnings .
Significant Drug Interactions
ritonavir, a strong CYP3A inhibitor, may cause incr. exposure of certain medications, resulting in potential severe, life-threatening or fatal events; review all medications to assess potential drug interactions and determine if dose adjustment, interruption, or additional monitoring required; consider benefit of reduced hospitalization and death and risk of appropriate drug interaction management
Adult Dosing .
Dosage forms: TAB (5-day pack): nirmatrelvir 150 mg x20 and ritonavir 100 mg x10; TAB (moderate renal impairment 5-day pack): nirmatrelvir 150 mg x10 and ritonavir 100 mg x10; TAB (severe renal impairment 5-day pack): nirmatrelvir 150 mg x6 and ritonavir 100 mg x5
COVID-19, mild-moderate
- [1 dose PO bid x5 days]
- Start: ASAP w/in 5 days of symptom onset; Info: for patients at high risk for severe disease incl. hospitalization or death; 1 dose = 300 mg nirmatrelvir + 100 mg ritonavir; do not cut/crush/chew tab
renal dosing
- [see below]
- eGFR 30-59: nirmatrelvir 150 mg + ritonavir 100 mg bid; eGFR <30: nirmatrelvir 300 mg + ritonavir 100 mg x1, then nirmatrelvir 150 mg + ritonavir 100 mg qd x4 days
- HD: nirmatrelvir 300 mg + ritonavir 100 mg x1, then nirmatrelvir 150 mg + ritonavir 100 mg qd x4 days, on dialysis days admin. after dialysis; no supplement; PD: not defined
hepatic dosing
- [see below]
- Child-Pugh Class A or B: no adjustment; Child-Pugh Class C: not defined
Peds Dosing .
- Dosage forms: TAB (5-day pack): nirmatrelvir 150 mg x20 and ritonavir 100 mg x10; TAB (moderate renal impairment 5-day pack): nirmatrelvir 150 mg x10 and ritonavir 100 mg x10; TAB (severe renal impairment 5-day pack): nirmatrelvir 150 mg x6 and ritonavir 100 mg x5
Special Note
- [FDA emergency use authorization (EUA)]
- Info: for mild-moderate COVID-19 in patients at high risk for severe disease incl. hospitalization or death; avail. from Pfizer Inc. or authorized distributors as directed by US government; for clinical trial eligibility and enrollment info, check www.clinicaltrials.gov
- [mandatory reporting for EUA]
- Info: serious medication errors and adverse events must be reported to FDA MedWatch (www.fda.gov/medwatch/report.htm or 1-800-FDA-1088) and Pfizer Inc. (1-800-438-1985)
COVID-19, mild-moderate
- [12 yo and older, >40 kg]
- Dose: 1 dose PO bid x5 days; Start: ASAP w/in 5 days of symptom onset; Info: for patients at high risk for severe disease incl. hospitalization or death; 1 dose = 300 mg nirmatrelvir + 100 mg ritonavir; do not cut/crush/chew tab
renal dosing
- [see below]
- eGFR 30-59: nirmatrelvir 150 mg + ritonavir 100 mg bid; eGFR <30: nirmatrelvir 300 mg + ritonavir 100 mg x1, then nirmatrelvir 150 mg + ritonavir 100 mg qd x4 days
- HD: nirmatrelvir 300 mg + ritonavir 100 mg x1, then nirmatrelvir 150 mg + ritonavir 100 mg qd x4 days, on dialysis days admin. after dialysis; no supplement; PD: not defined
hepatic dosing
- [see below]
- Child-Pugh Class A or B: no adjustment; Child-Pugh Class C: not defined